Heidi Cuthbert

Yancoal Australia (ASX:YAL) completed its acquisition of an 80% interest in the Kestrel coal mine.

Data#3 (ASX:DTL) announced that gross profit and earnings for the first half of FY27 have tracked ahead of expectations.

Ampol (ASX:ALD) has entered into an agreement to acquire 100% of Fast Cities Australia, known as Evie Networks, for $225 million.

Cettire (ASX:CTT) founder and CEO Dean Mintz purchased 11,437,140 shares in the online luxury retailer for more than $2.7 million.

Wallets linked to Bitget’s $387.5 million hack have moved about $3.9 million into Zcash (ZEC), according to a CoinDesk report.

LTR Pharma (ASX:LTP) completed its final Phase 2 clinical report, confirming that its nasal spray achieved peak blood concentration in 10 minutes.

Firmus Technologies has appointed four joint lead managers for its planned $7.2 billion initial public offering.

Atara Biotherapeutics (NASDAQ:ATRA) announced that partner Pierre Fabre Pharmaceuticals resubmitted the Biologics License Application (BLA) for tabelecleucel to the U.S. Food and Drug Administration for treatment of relapsed or refractory EBV-positive post-transplant lymphoproliferative disease.

Sarepta Therapeutics (NASDAQ:SRPT) presented new clinical data showing ELEVIDYS (delandistrogene moxeparvovec) was associated with functional benefits in older ambulatory patients with Duchenne muscular dystrophy at the World Muscle Society Congress 2026.

Eli Lilly (NYSE:LLY) reported Phase 3b ADtouch study results showing EBGLYSS monotherapy met its primary and secondary endpoints in adults and adolescents with hand-and-foot atopic dermatitis.